<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01553058</url>
  </required_header>
  <id_info>
    <org_study_id>814278</org_study_id>
    <nct_id>NCT01553058</nct_id>
  </id_info>
  <brief_title>Vascular Inflammation in Psoriasis Trial (The VIP Trial)</brief_title>
  <acronym>VIP</acronym>
  <official_title>A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of adalimumab (Humira), when compared to
      NB-UVB (narrow-band ultraviolet B) phototherapy or placebo (an inactive substance that may
      resemble an active substance but has no medical value) injection. The study will compare the
      effects of each on systemic inflammation and cardiovascular disease risk factors in subjects
      diagnosed with moderate to severe psoriasis.

      This study will look for systemic vascular inflammation in subjects with a test called
      FDG-PET/CT (Fluorodeoxyglucose-positron emission tomography/computed tomography). The study
      will also look for cardio metabolic (heart disease and metabolic factors such as diabetes)
      identifiers in the blood. A blood sample will be taken that will look for these markers
      identifying high cholesterol, cholesterol efflux function (the ability of cholesterol to move
      in the body), metabolic factors, and inflammation.

      This study will also assess the effect of adalimumab (Humira), when compared to NB-UVB
      phototherapy or placebo injection on psoriasis activity and severity. The study will also
      compare the safety of adalimumab (Humira) to NB-UVB phototherapy or placebo injection. This
      study will also evaluate subjects' reported outcomes through a questionnaire that will assess
      quality-of-life in subjects living with psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">October 27, 2016</completion_date>
  <primary_completion_date type="Actual">August 8, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Vascular Inflammation</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>Change in total vascular inflammation of five aortic segments as assessed on FDG-PET/CT between baseline and week 12. The arterial uptake of FDG is measured by the standardized uptake value (SUV) max divided by the venous SUV mean yielding a target to background ratio (TBR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiometabolic Biomarkers: Total Cholesterol</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on total cholesterol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiometabolic Biomarkers: Cholesterol Efflux</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on cholesterol efflux capacity. The ability to promote cholesterol efflux from macrophages is a classic function of HDL that is thought to be an important mechanism by which HDL protects against atherosclerosis. HDL cholesterol efflux capacity assays are performed based on published methods using J774 cells derived from a murine macrophage cell line (Mehta NN Atherosclerosis 2012). Efflux is calculated as a unitless measure by using the following formula: [(µCi of 3H-cholesterol in media containing apoB-depleted subject plasma - µCi of 3H-cholesterol in plasma-free media) / (µCi of 3H-cholesterol in media containing apoB-depleted pooled control plasma-µCi of 3H-cholesterol in pooled control plasma-free media)]. The pooled plasma was obtained from five healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiometabolic Biomarkers: Low Density Lipoprotein Particle Total</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on low density lipoprotein particle total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiometabolic Biomarkers: High Density Lipoprotein Particle Total</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on high density lipoprotein particle total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiometabolic Biomarkers: Log Insulin</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log insulin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiometabolic Biomarkers: Log Adiponectin</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log adiponectin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiometabolic Biomarkers: Log Leptin</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log leptin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiometabolic Biomarkers: Log C-reactive Protein</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log C-reactive protein (CRP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiometabolic Biomarkers: Log Tumor Necrosis Factor-alpha</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log Tumor necrosis factor-alpha.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiometabolic Biomarkers: Log Interleukin 6</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log interleukin 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cardiometabolic Biomarkers: GlycA</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on GlycA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Psoriasis Activity (PASI-75 and PGA)</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>Psoriasis activity will be assessed using standard psoriasis measurements, PASI75 and PGA Clear/Almost Clear</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-reported Outcomes-EuroQol EQ-5D</measure>
    <time_frame>Baseline -Week 12</time_frame>
    <description>EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a scale ranging from 1 (no health state problem) to 3 (extreme health state problems). The EQ VAS records the patient's self-rated health on a vertical visual analogue scale ranging from 0, worst health state, to 100, best health state. A scoring function is used to assign a value (i.e., EQ-5D™ index score) to self-reported health states from a set of population-based preference weights. For the U.S. general population, the possible EQ-5D index scores range from -0.11 to 1.0 where 0.0 = death and 1.0 = perfect health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-reported Outcomes-Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>Patient reported quality of life outcomes will be assessed using DLQI. The DLQI is calculated by summing the score of 10 questions regarding impact of skin condition on daily life resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-reported Outcomes-MEDFICTS Dietary Assessment)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Patient reported dietary outcomes will be assessed using MEDFICTS (Meats, Eggs, Dairy, Fried foods, fat In baked goods, Convenience foods, fats added at the Table, and Snacks), a brief dietary assessment instrument for properly assessing cardiovascular diet. The questionnaire yields a continuous score (ranging from 0 to 216), with a score of &lt;40 indicating adherence to the Therapeutic Lifestyle Changes (TLC) diet (intake of &lt;7% of energy from saturated fat, &lt;30% of energy from total fat, and &lt;200 mg dietary cholesterol/day).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient-reported Outcomes-International Physical Activity Questionnaire (IPAQ)</measure>
    <time_frame>Baseline week 4, 8 and 12</time_frame>
    <description>Patient reported physical activity will be assessed using IPAQ. IPAQ is an instrument designed primarily for population surveillance of physical activity among adults with activity measured in metabolic equivalent (MET)-minutes per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events.</measure>
    <time_frame>Baseline - Week 12</time_frame>
    <description>Safety will be assessed by comparing how many patients have adverse events depending on whether they are on adalimumab, as compared to NB-UVB phototherapy or placebo.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Psoriasis</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Adalimumab (Humira)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of the active drug Humira.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of placebo in place of active Humira injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NB-UVB phototherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NB-UVB Phototherapy 3 times per week, no other intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab (Humira)</intervention_name>
    <description>Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
    <arm_group_label>Adalimumab (Humira)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Injection</intervention_name>
    <description>Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
    <arm_group_label>Placebo Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NB-UVB phototherapy</intervention_name>
    <description>Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
    <arm_group_label>NB-UVB phototherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females 18 years of age and older.

          2. Clinical diagnosis of psoriasis for at least 6 months as determined by subject
             interview of his/her medical history and confirmation of diagnosis through physical
             examination by Investigator.

          3. Stable plaque psoriasis for at least 2 months before Screening and at Baseline (Week
             0) as determined by subject interview of his/her medical history.

          4. Moderate to severe psoriasis defined by ≥ 10 percent Body Surface Area (BSA)
             involvement at the Baseline (Week 0) visit.

          5. PASI (psoriasis assessment and severity index) score of ≥ 12 at the Baseline (Week 0)
             visit.

          6. Subject is a candidate for systemic therapy or phototherapy and has active psoriasis
             despite prior treatment with topical agents.

          7. Women are eligible to participate in the study if they meet one of the following
             criteria:

               1. Women of childbearing potential who are willing to undergo regular pregnancy
                  testing and agree to use one method of contraception throughout the study are
                  eligible to participate

               2. Women who are postmenopausal (for at least one year), sterile, or hysterectomized
                  are eligible to participate

               3. Women who have undergone tubal ligation are eligible to participate

               4. Women who agree to be sexually abstinent, defined as total abstinence from sexual
                  intercourse, as a form of contraception are eligible to participate in the study.

          8. Subject is judged to be in good general health as determined by the Principal
             Investigator based upon the results of medical history, laboratory profile, physical
             examination, and 12-lead electrocardiogram (ECG) performed at screening.

          9. Able and willing to give written informed consent and to comply with requirements of
             this study protocol.

        Exclusion Criteria:

          1. Previous adverse event following exposure to a TNF-alpha antagonist and/or UV
             phototherapy that led to discontinuation of either of these therapies and
             contraindicates future treatment.

          2. Previous lack of response to a TNF-alpha antagonist and/or UV phototherapy that led to
             discontinuation of either of these therapies.

          3. Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis,
             medication-induced or medication-exacerbated psoriasis, or new onset guttate
             psoriasis.

          4. Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or
             viral) that may interfere with evaluation of psoriasis.

          5. Cannot avoid UVB phototherapy for at least 14 days prior to the Baseline (Week 0)
             visit.

          6. Cannot avoid psoralen-UVA phototherapy for at least 30 days prior to the Baseline
             (Week 0) visit and during the study.

          7. Cannot discontinue systemic therapies for the treatment of psoriasis, or systemic
             therapies known to improve psoriasis, during the study:

               -  Systemic (investigational or marketed) therapies must be discontinued at least 30
                  days prior to the Baseline (Week 0) visit except for biologics.

                    -  All biologics, except ustekinumab, must be discontinued for at least 90 days
                       prior to Baseline (Week 0).

                    -  The IL-12/IL-23 antagonist ustekinumab (half-life of 45.6 ± 80.2 days) must
                       be discontinued for at least 180 days prior to Baseline (Week 0).

               -  Investigational agents must be discontinued at least 30 days or 5 half-lives
                  (whichever is longer) prior to the Baseline (Week 0) visit.

          8. Subject is taking or requires oral or injectable corticosteroids during the study.
             Inhaled corticosteroids for stable medical conditions are allowed.

          9. Poorly controlled medical condition, such as unstable ischemic heart disease,
             congestive heart failure, recent cerebrovascular accidents, psychiatric disease
             requiring frequent hospitalization, and any other condition, which, in the opinion of
             the Investigator, would put the subject at risk by participation in the study.

         10. History of diabetes mellitus, type 1 or type 2 - note that patients with type 2
             diabetes may be enrolled if the duration of diabetes is &lt;10 years and HbA1c is &lt;7.0%)

         11. Uncontrolled hypertension, with measured systolic blood pressure &gt;180 mmHg or
             diastolic blood pressure &gt;90 mmHg

         12. History of demyelinating diseases or lupus.

         13. Subject has infection or risk factors for severe infections, for example:

               -  Positive serology or known history of HIV, hepatitis B or C, or other severe,
                  recurrent, or persistent infections;

               -  Excessive immunosuppression or other factors associated with it, including human
                  immunodeficiency virus infection;

               -  Active tuberculosis (TB) disease;

               -  Evidence of latent TB infection demonstrated by Purified Protein Derivative (PPD)
                  ≥ 5 mm of induration or positive Quantiferon-GOLD results; except if prophylactic
                  treatment for TB, as recommended by local guidelines, is initiated prior to
                  administration of study drug or if there is documentation that the subject has
                  received prophylactic treatment for TB previously.

               -  Any other significant infection requiring hospitalization or intravenous (IV)
                  antibiotics in the month prior to Baseline;

               -  Infection requiring treatment with oral or parenteral antibiotics within 14 days
                  prior to Baseline;

               -  Subject has received vaccination with Bacille Calmette-Guerin (BCG) within 365
                  days prior to Screening;

               -  Subject has received vaccination with a live viral agent 30 days prior to
                  Screening or will require a live vaccination during study participation including
                  up to 30 days after the last dose of study drug.

         14. Subject has history of hematological or solid malignancy other than successfully
             treated basal cell carcinoma, non-metastatic cutaneous squamous cell carcinoma or
             cervical carcinoma in situ.

         15. Female subject who is pregnant or breast-feeding or considering becoming pregnant
             during the study.

         16. Screening clinical laboratory analyses showing any of the following abnormal results:

               -  Hemoglobin (Hgb) &lt; 10 g/dL in females or &lt;12 g/dL in males;

               -  White blood cell (WBC) count &lt;2.5 x 109/L

                  o Subject can be included if WBC count is &lt;2.5 x x 109/L and absolute neutrophil
                  count (ANC) is &gt;1000 cells / mm3.

               -  WBC count &gt; 15 x 109/L;

               -  Platelet count &lt; 100 x 109/L;

               -  Serum aspartate transaminase (AST) or alanine transaminase (ALT) &gt;2.5 upper
                  limits of normal (ULN);

               -  Serum total bilirubin ≥2 mg/dL (≥26 µmol/L); or

               -  Serum creatinine &gt;1.6 mg/dL (&gt;141 µmol/L).

         17. Recent history of substance abuse or psychiatric illness that could preclude
             compliance with the protocol.

         18. History of any substance abuse within 365 days of screening visit

         19. Alcohol use &gt;14 drinks per week at the screening visit or within 30 days of the
             screening period

         20. If subject is on cholesterol-lowering medication (e.g. statin), dose and form of
             medication must be stable for 90 days prior to week 0 and remain stable throughout the
             duration of the study.

         21. History of photosensitivity of medical condition that may be exacerbated by UV
             exposures such as lupus or dermatomyositis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Gelfand, MD MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Health System</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart, Lung, and Blood Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo Medical Group</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menter Dermatology Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <results_first_submitted>August 4, 2017</results_first_submitted>
  <results_first_submitted_qc>April 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2018</results_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>FDG/PET-CT</keyword>
  <keyword>NB-UVB Phototherapy</keyword>
  <keyword>Vascular Inflammation</keyword>
  <keyword>Lipid Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adalimumab (Humira)</title>
          <description>Injection of the active drug Humira.
Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Injection</title>
          <description>Injection of placebo in place of active Humira injection.
Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
        </group>
        <group group_id="P3">
          <title>NB-UVB Phototherapy</title>
          <description>NB-UVB Phototherapy 3 times per week, no other intervention.
NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adalimumab (Humira)</title>
          <description>Injection of the active drug Humira.
Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Injection</title>
          <description>Injection of placebo in place of active Humira injection.
Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
        </group>
        <group group_id="B3">
          <title>NB-UVB Phototherapy</title>
          <description>NB-UVB Phototherapy 3 times per week, no other intervention.
NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.15" spread="13.97"/>
                    <measurement group_id="B2" value="44.32" spread="14.50"/>
                    <measurement group_id="B3" value="41.97" spread="13.97"/>
                    <measurement group_id="B4" value="43.46" spread="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Psoriasis Duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.94" spread="14.73"/>
                    <measurement group_id="B2" value="19.29" spread="13.59"/>
                    <measurement group_id="B3" value="15.87" spread="13.55"/>
                    <measurement group_id="B4" value="16.7" spread="13.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Psoriatic Arthritis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.93" spread="7.42"/>
                    <measurement group_id="B2" value="31.95" spread="7.74"/>
                    <measurement group_id="B3" value="32.61" spread="8.66"/>
                    <measurement group_id="B4" value="31.83" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Cardiovascular Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hyperlipidemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Statin Use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>10year Framingham Risk %</title>
          <description>Absolute risk of developing a first cardiovascular disease (CVD) event (coronary death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke, transient ischemic attack, peripheral artery disease, heart failure) within 10 years. The units are in 10-year risk percentage.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.43" spread="7.75"/>
                    <measurement group_id="B2" value="7.91" spread="8.83"/>
                    <measurement group_id="B3" value="6.12" spread="7.68"/>
                    <measurement group_id="B4" value="7.53" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area</title>
          <description>Body Surface Area (BSA) is defined by how much (percentage) of the total body surface area is affected:
Mild psoriasis: &lt;5% of BSA Moderate psoriasis: 5-10% of BSA Severe psoriasis: &gt;10% of BSA (Note: 1% of BSA is approximately equal to the palm of the patient’s hand, excluding fingers)</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.39" spread="14.48"/>
                    <measurement group_id="B2" value="25.70" spread="15.02"/>
                    <measurement group_id="B3" value="22.96" spread="13.37"/>
                    <measurement group_id="B4" value="23.98" spread="14.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PASI (Psoriasis Area and Severity Index)</title>
          <description>PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.89" spread="5.59"/>
                    <measurement group_id="B2" value="18.33" spread="7.64"/>
                    <measurement group_id="B3" value="19.32" spread="8"/>
                    <measurement group_id="B4" value="18.85" spread="7.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PGA (Physician's Global Assessment)</title>
          <description>The PGA is an average assessment of all psoriatic lesions based on erythema, scale, and induration with score ranging from 0 (no evidence of disease) to 5 (maximal disease).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.36" spread=".56"/>
                    <measurement group_id="B2" value="3.22" spread=".59"/>
                    <measurement group_id="B3" value="3.27" spread=".66"/>
                    <measurement group_id="B4" value="3.28" spread=".6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DLQI (Dermatology Quality of Life Index)</title>
          <description>The DLQI is calculated by summing the score of 10 questions regarding impact of skin condition on daily life resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.88" spread="5.53"/>
                    <measurement group_id="B2" value="13.48" spread="7.58"/>
                    <measurement group_id="B3" value="14.61" spread="6.52"/>
                    <measurement group_id="B4" value="14.68" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Phototherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>H/O Oral Systemics</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>H/O Biologics</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Vascular Inflammation</title>
        <description>Change in total vascular inflammation of five aortic segments as assessed on FDG-PET/CT between baseline and week 12. The arterial uptake of FDG is measured by the standardized uptake value (SUV) max divided by the venous SUV mean yielding a target to background ratio (TBR).</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira.
Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection.
Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention.
NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vascular Inflammation</title>
          <description>Change in total vascular inflammation of five aortic segments as assessed on FDG-PET/CT between baseline and week 12. The arterial uptake of FDG is measured by the standardized uptake value (SUV) max divided by the venous SUV mean yielding a target to background ratio (TBR).</description>
          <units>Tissue-to-background ratio (TBR)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.067" spread=".213"/>
                    <measurement group_id="O2" value="-.052" spread=".112"/>
                    <measurement group_id="O3" value="-.079" spread=".020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of Differences</non_inferiority_desc>
            <p_value>0.795</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.647</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiometabolic Biomarkers: Total Cholesterol</title>
        <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on total cholesterol.</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira. Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection. Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention. NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiometabolic Biomarkers: Total Cholesterol</title>
          <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on total cholesterol.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="21.25"/>
                    <measurement group_id="O2" value="5.00" spread="25.22"/>
                    <measurement group_id="O3" value="3.15" spread="32.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.386</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of Differences</non_inferiority_desc>
            <p_value>0.280</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Psoriasis Activity (PASI-75 and PGA)</title>
        <description>Psoriasis activity will be assessed using standard psoriasis measurements, PASI75 and PGA Clear/Almost Clear</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira.
Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection.
Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention.
NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Psoriasis Activity (PASI-75 and PGA)</title>
          <description>Psoriasis activity will be assessed using standard psoriasis measurements, PASI75 and PGA Clear/Almost Clear</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA Clear/Almost Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient-reported Outcomes-EuroQol EQ-5D</title>
        <description>EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a scale ranging from 1 (no health state problem) to 3 (extreme health state problems). The EQ VAS records the patient’s self-rated health on a vertical visual analogue scale ranging from 0, worst health state, to 100, best health state. A scoring function is used to assign a value (i.e., EQ-5D™ index score) to self-reported health states from a set of population-based preference weights. For the U.S. general population, the possible EQ-5D index scores range from -0.11 to 1.0 where 0.0 = death and 1.0 = perfect health.</description>
        <time_frame>Baseline -Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira.
Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection.
Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention.
NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient-reported Outcomes-EuroQol EQ-5D</title>
          <description>EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life that can be used in a wide range of health conditions and treatments. The EQ-5D consists of a descriptive system and the EQ VAS. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a scale ranging from 1 (no health state problem) to 3 (extreme health state problems). The EQ VAS records the patient’s self-rated health on a vertical visual analogue scale ranging from 0, worst health state, to 100, best health state. A scoring function is used to assign a value (i.e., EQ-5D™ index score) to self-reported health states from a set of population-based preference weights. For the U.S. general population, the possible EQ-5D index scores range from -0.11 to 1.0 where 0.0 = death and 1.0 = perfect health.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".07" spread=".14"/>
                    <measurement group_id="O2" value=".0" spread=".17"/>
                    <measurement group_id="O3" value=".16" spread=".19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient-reported Outcomes-Dermatology Life Quality Index (DLQI)</title>
        <description>Patient reported quality of life outcomes will be assessed using DLQI. The DLQI is calculated by summing the score of 10 questions regarding impact of skin condition on daily life resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira.
Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection.
Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention.
NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient-reported Outcomes-Dermatology Life Quality Index (DLQI)</title>
          <description>Patient reported quality of life outcomes will be assessed using DLQI. The DLQI is calculated by summing the score of 10 questions regarding impact of skin condition on daily life resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.91" spread="8.77"/>
                    <measurement group_id="O2" value="-3.73" spread="8"/>
                    <measurement group_id="O3" value="-9.27" spread="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient-reported Outcomes-MEDFICTS Dietary Assessment)</title>
        <description>Patient reported dietary outcomes will be assessed using MEDFICTS (Meats, Eggs, Dairy, Fried foods, fat In baked goods, Convenience foods, fats added at the Table, and Snacks), a brief dietary assessment instrument for properly assessing cardiovascular diet. The questionnaire yields a continuous score (ranging from 0 to 216), with a score of &lt;40 indicating adherence to the Therapeutic Lifestyle Changes (TLC) diet (intake of &lt;7% of energy from saturated fat, &lt;30% of energy from total fat, and &lt;200 mg dietary cholesterol/day).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira.
Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection.
Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention.
NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient-reported Outcomes-MEDFICTS Dietary Assessment)</title>
          <description>Patient reported dietary outcomes will be assessed using MEDFICTS (Meats, Eggs, Dairy, Fried foods, fat In baked goods, Convenience foods, fats added at the Table, and Snacks), a brief dietary assessment instrument for properly assessing cardiovascular diet. The questionnaire yields a continuous score (ranging from 0 to 216), with a score of &lt;40 indicating adherence to the Therapeutic Lifestyle Changes (TLC) diet (intake of &lt;7% of energy from saturated fat, &lt;30% of energy from total fat, and &lt;200 mg dietary cholesterol/day).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.17" spread="17.47"/>
                    <measurement group_id="O2" value="-13.66" spread="28.59"/>
                    <measurement group_id="O3" value="-16.29" spread="20.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Patient-reported Outcomes-International Physical Activity Questionnaire (IPAQ)</title>
        <description>Patient reported physical activity will be assessed using IPAQ. IPAQ is an instrument designed primarily for population surveillance of physical activity among adults with activity measured in metabolic equivalent (MET)-minutes per week.</description>
        <time_frame>Baseline week 4, 8 and 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira.
Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection.
Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention.
NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient-reported Outcomes-International Physical Activity Questionnaire (IPAQ)</title>
          <description>Patient reported physical activity will be assessed using IPAQ. IPAQ is an instrument designed primarily for population surveillance of physical activity among adults with activity measured in metabolic equivalent (MET)-minutes per week.</description>
          <units>MET-minutes/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1282" spread="4837"/>
                    <measurement group_id="O2" value="141" spread="2921"/>
                    <measurement group_id="O3" value="18" spread="2994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events.</title>
        <description>Safety will be assessed by comparing how many patients have adverse events depending on whether they are on adalimumab, as compared to NB-UVB phototherapy or placebo.</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira.
Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection.
Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention.
NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events.</title>
          <description>Safety will be assessed by comparing how many patients have adverse events depending on whether they are on adalimumab, as compared to NB-UVB phototherapy or placebo.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pruritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>photosensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>upper respiratory infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>joint range of motion decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tooth infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiometabolic Biomarkers: Cholesterol Efflux</title>
        <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on cholesterol efflux capacity. The ability to promote cholesterol efflux from macrophages is a classic function of HDL that is thought to be an important mechanism by which HDL protects against atherosclerosis. HDL cholesterol efflux capacity assays are performed based on published methods using J774 cells derived from a murine macrophage cell line (Mehta NN Atherosclerosis 2012). Efflux is calculated as a unitless measure by using the following formula: [(µCi of 3H-cholesterol in media containing apoB-depleted subject plasma - µCi of 3H-cholesterol in plasma-free media) / (µCi of 3H-cholesterol in media containing apoB-depleted pooled control plasma-µCi of 3H-cholesterol in pooled control plasma-free media)]. The pooled plasma was obtained from five healthy volunteers.</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira. Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection. Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention. NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiometabolic Biomarkers: Cholesterol Efflux</title>
          <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on cholesterol efflux capacity. The ability to promote cholesterol efflux from macrophages is a classic function of HDL that is thought to be an important mechanism by which HDL protects against atherosclerosis. HDL cholesterol efflux capacity assays are performed based on published methods using J774 cells derived from a murine macrophage cell line (Mehta NN Atherosclerosis 2012). Efflux is calculated as a unitless measure by using the following formula: [(µCi of 3H-cholesterol in media containing apoB-depleted subject plasma - µCi of 3H-cholesterol in plasma-free media) / (µCi of 3H-cholesterol in media containing apoB-depleted pooled control plasma-µCi of 3H-cholesterol in pooled control plasma-free media)]. The pooled plasma was obtained from five healthy volunteers.</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.25"/>
                    <measurement group_id="O2" value="0.00" spread="0.15"/>
                    <measurement group_id="O3" value="0.04" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of Differences</non_inferiority_desc>
            <p_value>0.357</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of Differences</non_inferiority_desc>
            <p_value>0.496</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiometabolic Biomarkers: Low Density Lipoprotein Particle Total</title>
        <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on low density lipoprotein particle total.</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira. Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>njection of placebo in place of active Humira injection. Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention. NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiometabolic Biomarkers: Low Density Lipoprotein Particle Total</title>
          <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on low density lipoprotein particle total.</description>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.70" spread="263.32"/>
                    <measurement group_id="O2" value="-34.90" spread="319.42"/>
                    <measurement group_id="O3" value="17.42" spread="187.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of Differences</non_inferiority_desc>
            <p_value>0.897</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.467</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiometabolic Biomarkers: High Density Lipoprotein Particle Total</title>
        <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on high density lipoprotein particle total.</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira. Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection. Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention. NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiometabolic Biomarkers: High Density Lipoprotein Particle Total</title>
          <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on high density lipoprotein particle total.</description>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="4.00"/>
                    <measurement group_id="O2" value="-1.97" spread="7.03"/>
                    <measurement group_id="O3" value="1.35" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.089</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.030</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiometabolic Biomarkers: Log Insulin</title>
        <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log insulin.</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira. Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection. Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention. NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiometabolic Biomarkers: Log Insulin</title>
          <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log insulin.</description>
          <units>log(pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.71"/>
                    <measurement group_id="O2" value="-0.21" spread="0.74"/>
                    <measurement group_id="O3" value="-0.13" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.934</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.679</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiometabolic Biomarkers: Log Adiponectin</title>
        <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log adiponectin.</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira. Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection. Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention. NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiometabolic Biomarkers: Log Adiponectin</title>
          <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log adiponectin.</description>
          <units>log(ug/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="2.05"/>
                    <measurement group_id="O2" value="0.07" spread="0.45"/>
                    <measurement group_id="O3" value="-0.08" spread=".41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.672</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.655</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiometabolic Biomarkers: Log Leptin</title>
        <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log leptin.</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira. Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection. Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention. NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiometabolic Biomarkers: Log Leptin</title>
          <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log leptin.</description>
          <units>log(pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.55"/>
                    <measurement group_id="O2" value="0.03" spread="0.47"/>
                    <measurement group_id="O3" value="0.08" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.504</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.695</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiometabolic Biomarkers: Log C-reactive Protein</title>
        <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log C-reactive protein (CRP).</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira. Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection. Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention. NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiometabolic Biomarkers: Log C-reactive Protein</title>
          <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log C-reactive protein (CRP).</description>
          <units>log(pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="1.00"/>
                    <measurement group_id="O2" value="0.35" spread="1.06"/>
                    <measurement group_id="O3" value="-0.50" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.009</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiometabolic Biomarkers: Log Tumor Necrosis Factor-alpha</title>
        <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log Tumor necrosis factor-alpha.</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira. Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection. Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention. NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiometabolic Biomarkers: Log Tumor Necrosis Factor-alpha</title>
          <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log Tumor necrosis factor-alpha.</description>
          <units>log(pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.33"/>
                    <measurement group_id="O2" value="0.14" spread="0.38"/>
                    <measurement group_id="O3" value="-0.04" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of Differences</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.065</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiometabolic Biomarkers: Log Interleukin 6</title>
        <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log interleukin 6.</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira. Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection. Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention. NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiometabolic Biomarkers: Log Interleukin 6</title>
          <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on log interleukin 6.</description>
          <units>log(pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="1.08"/>
                    <measurement group_id="O2" value="0.20" spread="0.99"/>
                    <measurement group_id="O3" value="-0.49" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.007</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.019</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Cardiometabolic Biomarkers: GlycA</title>
        <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on GlycA</description>
        <time_frame>Baseline - Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira)</title>
            <description>Injection of the active drug Humira. Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Injection</title>
            <description>Injection of placebo in place of active Humira injection. Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
          </group>
          <group group_id="O3">
            <title>NB-UVB Phototherapy</title>
            <description>NB-UVB Phototherapy 3 times per week, no other intervention. NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cardiometabolic Biomarkers: GlycA</title>
          <description>To assess the effects of adalimumab, as compared to NB-UVB phototherapy or placebo, in patients with moderate to severe psoriasis on GlycA</description>
          <units>log(pg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.89" spread="40.38"/>
                    <measurement group_id="O2" value="5.28" spread="66.83"/>
                    <measurement group_id="O3" value="-1.92" spread="52.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.006</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Difference of differences</non_inferiority_desc>
            <p_value>0.628</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline - Week 12</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adalimumab (Humira)</title>
          <description>Injection of the active drug Humira.
Adalimumab (Humira): Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Injection</title>
          <description>Injection of placebo in place of active Humira injection.
Placebo Injection: Placebo injection will be given according to the same dose and schedule as the active comparator.</description>
        </group>
        <group group_id="E3">
          <title>NB-UVB Phototherapy</title>
          <description>NB-UVB Phototherapy 3 times per week, no other intervention.
NB-UVB phototherapy: Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>vasovagal syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>joint range of motion decrease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>photosensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suzette Baez VanderBeek, MPH</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-662-3514</phone>
      <email>suzettev@upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

